Podcast appearances and mentions of chris emerson

Fleet management group EROAD's business development manager Chris Emerson talks on this Fleet News Group podcast about increasing pressure on fleets to meet sustainability targets, the future of road funding and what is top of mind for fleet managers in 2023. “We know that a lot of very large organisations and government organisations are definitely feeling the pressure of the 2030 targets to get their fleets as sustainable as possible, to reduce emissions as much as possible,” said Emerson. Emerson was referring to United Nations' so-called Paris agreement to cut greenhouse emissions by 45 percent by 2030, compared with 2010 levels, in a quest to limit global warming, and climate change. He talks about EROAD's technology which helps fleets measure and manage their emissions, and identify vehicles that can be cut, or swapped to electric vehicles.

With a new album, Anomaly, having dropped late this year and various shows booked across a range of continents, music producer Chris Emerson (Whatsonot), sits down with Luke from his LA base to chat booging. From his sessions at the infamous Kelly Slater wave pool, to face numbing injuries at Shipsterns Bluff and how his bodyboarding journey all started on the Northern Beaches of NSW, this episode is not to be missed!

What So Not is an electronic music project driven by Chris Emerson aka Emoh Instead. He has won several awards and toured the world, performing at both Coachella and Lollapalooza. He has also worked with a dazzling array of artists, including our very own Daniel Johns. What So Not released his debut album Not All The Beautiful Things in 2018 and is about to release the follow up entitled Anomaly. His music has the power to transport you, from your world into his and from the dancefloor to somewhere that floats above reality. He's one of most exciting creatives in his field and we are delighted to welcome to The Good Stuff, What So Not . . .

The High Ground - S1E2 - Founder's Interview: Scientific Innovation & Effects-Based Cannabis with Chris Emerson of Level   Welcome Back to the High Ground, a Bi-Weekly Video Series in which I'm going to be interviewing Founders that Span All Categories in the California Cannabis Market. Today we speak with Chris Emerson, the Founder & CEO of Level, a Cannabis Products Brand in the Cannabis Capsules Space. We learn about his extensive Scientific Background, the Tech Boom in San Francisco that allured him to the city, and discover how he ended up on a cannabis farm in Mendocino.  He also shares how all these events have led to a deeper call in understanding the scientific innovations within the cannabis sector, which he believes has a vast landscape of opportunity with Effects-Based Cannabis Products. Today, he spearheads the Capsules and Effects-Based Cannabis Brand, Level & Shares his Thoughts on the Future of the Market in California, and Beyond. --- For More Information on Level Visit, TRICHOMES.com Headset Analytics: https://www.headset.io/  Chris Emerson's LinkedIn: https://www.linkedin.com/in/chris-emerson-ph-d-464b245a Level's Instagram: https://www.instagram.com/level.experience --- The High Ground podcast is produced in partnership with TRICHOMES dot com. Special thanks to the TRICHOMES production team. Our executive producer Claudio Miranda, and to all our incredible guests who make this show possible.

Subscribe to Mushroom podcasts and support original Australian music journalism. You'll get them early and ad-free. Only $4 per month. FREE trial on Apple Podcasts. The good and bad of the collab and why, Tones and I keeps beating the world and What So Not (aka Chris Emerson) talks Coachella 2015 breakthrough to now. Quiet heads up, the trailer for a NEW Mushroom podcast is out - Some of My Best Work. This Episode! Why do some collaborators smoke (Charli XCX, The Kid LaRoi, Gotye etc) and others choke (Madonna and Britney)? Sose brings up to speed with Tones and I's latest global achievement, pretty casual, you know. What So Not (aka Chris Emerson) recalls the 15 managers waiting for him after his Coachella 2015 set and how he picked up the pieces after once sleeping through the start of his first ever Las Vegas set. Now look at him! Hosts Mikey Cahill - Instagram / Twitter / Facebook / mikeycahill.com Sosefina Fuamoli - Instagram / Twitter / sosefinafuamoli.com Marcus Teague - Twitter / The Guardian / Bandcamp More Hit Different Facebook Group Hit Different on Mushroom.com Looking for a music documentary? Subscribe to 180 Grams, the stories of remarkable albums. Credits Producer/editor - Courtney Carthy, the Mushroom Group Theme music - Mark D'Angelo, The Backlot Studios Artwork - Mushroom Creative House Equipment - Audio TechnicaGet more Hit Different: http://mushroom.com/podcast/hit-differentSee omnystudio.com/listener for privacy information.

Chris Emerson and Jared Good join me for some Wolves talk. We chat about the Wolves recent struggles and how the Wolves can stop the bleeding. Make sure to like and subscribe for the best Wolves talk around!

The Wolves have put up three embarrassing performances in a row. You can blame Town's absence, but it goes way deeper then that. Myself and Chris Emerson break it all down in episode 1 of our new podcast.

In the inaugural episode of Legal Value Network's Off the Clock, Justin Ergler, a founding LVN board member, talks to Chris Emerson, Senior Director of Legal Operations and Innovation at Quarles & Brady. Justin and Chris discuss how law firms can provide value to clients outside of traditional legal work by providing assistance with legal operations. Law firms can also add value to client representations by providing insight and metrics about the legal work performed.

Chris Emerson, Ph.D., a small molecule chemist with a love for plant-based medicine, talks to us about using cannabinoids combined with terpenoids for targeted effects. He envisions a future of personalized medicine based on developing science, research, and empirical evidence to bring plant medicine back to the people. Chris Emerson, Ph.D., is the founder, CEO, and chief chemist of LEVEL, a company focusing on rare cannabinoids. When you get a doctorate in small molecule chemistry, your career traditionally goes in two directions: developing new drugs for big pharma or training new chemists. Chris opted for a third, uncharted direction: unlocking the true potential of cannabis to deliver brand-new highs and therapeutic solutions with targeted effects. Useful linksWebsite: https://levelexperience.com Blog Articles:- Our story: https://levelexperience.com/our-story/- Maverick beginnings—about Chris Emerson: https://levelexperience.com/maverick-beginnings-plant-love-meets-science/- How to stock your medicine cabinet: https://levelexperience.com/how-to-stock-your-medicine-cabinet-for-uncertain-times/- How to get started with cannabis: https://levelexperience.com/how-to-get-started-with-cannabis/- The Endocannabiniod System: https://levelexperience.com/the-human-ecs-system-and-cannabis/To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkhDisclaimer: The information presented in this podcast is for educational purposes only and is not intended to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

In this conversation, the third of a four-part series on mentorship, SSPI Director of Development and Innovation Lou Zacharilla speaks with two men whose careers have taken them to the top of their respective professions at some of the industry’s largest corporations. They share with us the unique advantages and challenges of mentorship “inside a giant.” Airbus is an international company and a leader in designing, manufacturing and delivering aerospace products. And with 133,671 employees, it certainly qualifies as a giant. Its US Space & Defence Group is led by Chris Emerson. Chris has served as president of the group since 2019, where he oversees the operations and strategy of all its companies in the USA. He also serves as Chairman of the Board. Founded in 1948 by David Ogilvy, this ad agency can be found in 132 offices in 83 countries around the world. Adweeks’ Agency of the Year in 2016, Ogilvy’s client list is long and ranges from American Express to Ikea to Samsung. Ben Levine serves as Executive Partner and Head of Global Partnerships from Ogilvy’s main office in New York. He is responsible for developing and growing strategic relations across the Ogilvy Group, its parent company WPP and external networks to find greater value for its clients. Ben also serves as Global Client Leader for the agency.

It’s no secret that achieving a truly targeted effect is the holy grail of the cannabis industry, but how close are we to making this a reality? Are designer cannabis products on the horizon?  Here to help answer this is Chris Emerson, co-founder and CEO of a unique company known as Level that’s working to disrupt the cannabis industry with products precisely tailored to every individual and every occasion. Learn more at https://www.levelblends.com  Key Takeaways: Chris’ background in chemistry and how it led him to the cannabis space An inside look at Level and its mission to provide a tailored cannabis experience to every patient and consumer How Chris’ extensive background in science allows him to think about cannabis products differently than most entrepreneurs in the industry Why Level sources its oils from strains high in CBD, CBG, and THCV and how this enhances the overall effect for consumers Chris’ efforts to find rare and unique cannabinoids for Level’s products and his discoveries to date A deep dive into Level’s tablinguals and pax vaporizer pods Chris’ work at Level determining new uses for cannabinoids, including everything from stimulants to hangover cures New and exciting initiatives at Level and Chris’ insight on what the cannabis industry will look like in the next 5-10 years

Today’s podcast, the last in an 8-part series on psychotropic medications, is an open-hearted conversation between Windhorse community members Emily Ashley, Joe Calcagno, Chris Emerson, and Eugenie Morton. Looking back, we initially didn’t anticipate spending this much time on meds. But once entering the discussion—and knowing how critical it is to accurately understand the issues at hand—we decided to deepen our presentation with Windhorse staff and clients who actually use or have used them. Today you’ll hear a conversation with people who have extensive personal experience in this territory. As we conclude this series, I want to again bring attention to a theme that’s pervaded these conversations: People understandably have strong opinions about psychotropic medications, and this has produced intense polarities in how they are viewed and used—or not used. At Windhorse we practice in a middle path that takes into consideration all the various conditions and elements that determine whether a person wants to use meds or not, and how to live well with that choice. Our collective experience includes so many stories within these polarities, like the man I met in the WCS Admissions process, after having been admitted for his 50th psychiatric hospitalization. Somehow the magnitude of the number 50 woke him up, and he realized that his life was just not working the way he was approaching it. So, he decided to see what would happen if he stayed on medications for his bipolar condition. A few years of stable life later, he was happier than he’d been in the last 25 years and had become a highly effective peer counselor. Or there is the client I’ve admired for over 25 years for her big heart and fierce determination, who stated early in our relationship that she “would rather die than take medications.” There was no question that she really meant it. Life for her has not been easy, but she’s learned over time about what accommodations must be made around her vulnerabilities and the vicissitudes of her extreme mind states. Another woman I recall vividly, probably in her mid-30s, was a high school teacher. We met about five years ago at a conference where an author—very well-known for his research on how the use of anti-psychotic medication is strongly contraindicated—had just presented. She had clearly been crying and pulled me aside to share how she always felt like such a failure when hearing these kinds of presentations. She hated the basic idea of meds, but every time she tried to go off of them, and she’d always done so with discipline, patience, and in collaboration with her psychiatrist, she ended up in the hospital. After losing a couple of jobs, she resigned herself to staying on the most minimal effective dosage possible. And so far, that actually felt okay. There’s also the client I’ve known since his teens, who in the last 20 years has learned how to accurately ground his life in simplicity, consistent discipline, work, and healthy relationships. He’s been medication-free for the last five years, with amazingly resilient stability of mind and moods. And one last story produced a bit of a surprise for me in the form of a rare, un-ambivalent declaration. I was having dinner recently with a former client whom I worked with in the early 1990s. Since we first met, he’s always been on high doses of atypical anti-psychotic medications and has also been passionately engaged in life: with various kinds of work, meditation, and most recently reconnecting with his art as an abstract painter. Though one of the most disciplined people I know, occasionally his meds will get a little out of focus and he’ll enter a period of mania. Somehow, by awareness and what appears to be extremely good fortune, he’s managed to not just miraculously stay out of the hospital but to survive these extreme episodes. At dinner I shared with him that we were doing these podcasts on medications, and that I’d like to know how he feels about his experience with meds. He immediately laughed and boomed, “I love my meds! They let me to have the life I have, with a lot of joy and connection to people. And a huge thing for me is that they allow me to actually connect with the magic in my life, as opposed to being swamped by it.” Today’s podcast, like all the others in this series, contains the voices of people who know the gravity of extreme mental states. From extensive experience, they also understand how critical it is to the process of recovery that one can discern dream states from reality. The subtle and exquisitely tricky sweet-spot of whether a psychotropic medication enhances that discernment or obscures it depends on so many very personal variables—indeed, one size truly does not fit all. We hope this has been helpful and please share it with your friends, Chuck Knapp

It’s no secret that achieving a truly targeted effect is the holy grail of the cannabis industry, but how close are we to making this a reality? Are designer cannabis products on the horizon?  Here to help answer this is Chris Emerson, co-founder and CEO of a unique company known as Level that’s working to disrupt the cannabis industry with products precisely tailored to every individual and every occasion. Learn more at https://www.levelblends.com  Key Takeaways: Chris’ background in chemistry and how it led him to the cannabis space An inside look at Level and its mission to provide a tailored cannabis experience to every patient and consumer How Chris’ extensive background in science allows him to think about cannabis products differently than most entrepreneurs in the industry Why Level sources its oils from strains high in CBD, CBG, and THCV and how this enhances the overall effect for consumers Chris’ efforts to find rare and unique cannabinoids for Level’s products and his discoveries to date A deep dive into Level’s tablinguals and pax vaporizer pods Chris’ work at Level determining new uses for cannabinoids, including everything from stimulants to hangover cures New and exciting initiatives at Level and Chris’ insight on what the cannabis industry will look like in the next 5-10 years

On iC this week, Brandon sits down with Chris Emerson PhD of Level. Chris and his team have built one of the most interesting and innovative brands in the cannabis industry. Level is a cannabinoid company that focuses on creating targeted effects for consumers using unique + rare cannabinoids. THCA, THCV, CBG, CBN, and CBC are just a few of the unique cannabinoids you will learn about this week. Level recently raised their Series A and they have appx 30 people now on their team as they expand across California. This episode is all about cannabis science, unique cannabinoids and formulations, and how Level is educating consumers around this new product experience. Level is a great example of the evolution of cannabis. Tune in, listen up, and get acquainted with Chris and Level! Support for this episode comes from NorCal Cannabis Company, the most complete cannabis ecosystem in California. Market analysis, consumer segmentation, and first party data analytics are helping NorCal Cannabis shape the industry in new ways, every day. From cultivation to production, delivery, retail, brands and beyond...THIS is CANNABIS! To learn more, visit: “www.thefutureofcannabis.com” for more details. Want to Support Independent Cannabis Media? Want to promote your product or service to our audience of decision makers? Email hi@investingincannabis.tv

Sat down with Chris Emerson at Steuben's in Denver. We talked about what makes good applications and dev teams. Web: https://sweetcode.io/developers-eating-the-world/ Youtube: https://youtu.be/xXmMg1HVhYk Instagram: https://www.instagram.com/devseatworld/ SC Twitter: https://www.twitter.com/sweetcodehq Chris Twitter: https://twitter.com/hoardinginfo Chris LinkedIn: https://www.linkedin.com/in/cloudproductandmarketing/

It’s no secret that achieving a truly targeted effect is the holy grail of the cannabis industry, but how close are we to making this a reality? Are designer cannabis products on the horizon?  Here to help answer this is Chris Emerson, co-founder and CEO of a unique company known as Level that’s working to disrupt the cannabis industry with products precisely tailored to every individual and every occasion. Learn more at https://www.levelblends.com    Key Takeaways: Chris’ background in chemistry and how it led him to the cannabis space An inside look at Level and its mission to provide a tailored cannabis experience to every patient and consumer How Chris’ extensive background in science allows him to think about cannabis products differently than most entrepreneurs in the industry Why Level sources its oils from strains high in CBD, CBG, and THCV and how this enhances the overall effect for consumers Chris’ efforts to find rare and unique cannabinoids for Level’s products and his discoveries to date A deep dive into Level’s tablinguals and pax vaporizer pods Chris’ work at Level determining new uses for cannabinoids, including everything from stimulants to hangover cures New and exciting initiatives at Level and Chris’ insight on what the cannabis industry will look like in the next 5-10 years  

Chris, Ben and Tim join Sam and Annie for more chat and improv. Follow Tiny Dynamite: https://twitter.com/DynamiteImprov Annie's "Sh*t Scripts: Bad Manors" https://www.brightonfringe.org/whats-on/sht-scripts-bad-manors-130690/ Follow Annie: https://twitter.com/realannieharris Follow Sam: https://twitter.com/samuelrae_ Follow the podcast: https://twitter.com/contrivedpod

On our 25th episode we discuss the chemical aspects of cannabis with scientist Chris Emerson. Chris co-founded Level, a company that prides itself on understanding the molecular levels of cannabis for all ages of users. Chris talks of all non-smokable forms of ingestion, including vapes and sublingual sprays. We discuss dosing specifics and the notion of isolating certain terrines, or more simply put: generically aiming for individual ailments. Chris sees well beyond THC and CBD, as far as what the plant actually offers. We speak with Ruby LaGrandeur about her cannabis beverage, LaGrandeur, a cranberry flavored non-alcoholic “champagne” that allows non-smokers to get in on the benefits of cannabis. Measurements of ingestion with a beverage makes people wary of how much to drink. Ruby says it's light and allows non-drinker/nonsmokers to join the party.

First Episode with friend and roommate Chris Emerson. Camp, phones, movies and more.

After 20 years and a series of aborted sequels, Lost Boys fans had pretty much given up hope on their favorite vampire saga returning to the big screen. But in 2008 a sequel finally found its way to release--The Lost Boys: The Tribe. Featuring an entirely new set of vampires in a new California town, Chris Emerson has to square off against a tribe of vampires led by Shane to save his little sister from becoming a full vampire. Direct to video sequels are rarely are as good as their theatrical origins, but could this film buck the trend by including Keifer Sutherland's half-brother as the head vampire, Corey Feldman reprising his gravely Edgar Frog voice, and a cameo from horror master Tom Savini? Listen to find out!

After 20 years and a series of aborted sequels, Lost Boys fans had pretty much given up hope on their favorite vampire saga returning to the big screen. But in 2008 a sequel finally found its way to release--The Lost Boys: The Tribe. Featuring an entirely new set of vampires in a new California town, Chris Emerson has to square off against a tribe of vampires led by Shane to save his little sister from becoming a full vampire. Direct to video sequels are rarely are as good as their theatrical origins, but could this film buck the trend by including Keifer Sutherland's half-brother as the head vampire, Corey Feldman reprising his gravely Edgar Frog voice, and a cameo from horror master Tom Savini? Listen to find out!

After 20 years and a series of aborted sequels, Lost Boys fans had pretty much given up hope on their favorite vampire saga returning to the big screen. But in 2008 a sequel finally found its way to release--The Lost Boys: The Tribe. Featuring an entirely new set of vampires in a new California town, Chris Emerson has to square off against a tribe of vampires led by Shane to save his little sister from becoming a full vampire. Direct to video sequels are rarely are as good as their theatrical origins, but could this film buck the trend by including Keifer Sutherland's half-brother as the head vampire, Corey Feldman reprising his gravely Edgar Frog voice, and a cameo from horror master Tom Savini? Listen to find out!